← ANALYST RATINGS · TIPRANKS
Nuvectis Pharma (NVCT): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $36.50, the highest $39.00, the lowest $34.00. The average is +96.2% from the last price of $18.60.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $18.50 → $19.50+5.4% | Hold | +4.8% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 → $19.50+5.4% | Hold | +4.8% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.50 → $19.50+5.4% | Hold | +4.8% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.50 → $19.50+5.4% | Hold | +4.8% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.00 → $20.00+5.3% | Hold | +7.5% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $18.50 → $19.50+5.4% | Hold | +4.8% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| Naz Rahman★★★★★★★★★★#12198 · hits 36% · avg −7.5% | Maxim Group | $30.00 | Buy | +61.3% | Reiterated | 25.09.26on TipRanks 11:25 | −7.1%next day +3.7% · 5 days +8.6% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $39.00 | Buy | +109.7% | Reiterated | 24.09.26on TipRanks 10:35 | +2.7%next day −7.1% · 5 days −3.8% | ↗ |
| Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% | Cantor Fitzgerald | — | Buy | — | Initiated | 24.08.26on TipRanks 06:30 | +1.6%next day +8.1% · 5 days −5.2% | ↗ |
| Christopher Liu★★★★★★★★★★#2941 · hits 44% · avg +8.9% | Lucid Capital | $22.00 → $34.00+54.5% | Buy | +82.8% | Reiterated | 05.08.26on TipRanks 06:16 | −4.0%next day −2.1% · 5 days +1.1% | ↗ |
| Jonathan Aschoff★★★★★★★★★★#12373 · hits 29% · avg −21.0% | Roth MKM | $20.00 → $33.00+65.0% | Buy | +77.4% | Assigned | 06.07.26on TipRanks Jul 5 21:06 | −0.6%next day −1.7% · 5 days −5.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Nuvectis Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $34.00 at a price of $21.12 (+61.0%); now: $34.33 at $18.60 (+84.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 2 | 4 | 4 | 3 |
| Buy | 1 | 3 | 3 | 3 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.24 (from $-0.28 to $-0.21). Last quarter: $-0.30.
Best top-analyst consensus in the sector · Healthcare
About Nuvectis Pharma
- CEO: Ron Bentsur
- Employees: 16
- 1 Bridge Plaza, Fort Lee, NJ, 07024, US
- www.nuvectis.com
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Data from the stock’s TipRanks forecast page, read 179 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗